The Red Roadmasterâ€™s US Market Re-cap + Stock Talk â„˘
August 13, 2009
The US Fed says the economy is leveling out, leaving interest rates unchanged for now.
Re-cap of the US Stock Market Action for August 12, 2009 US stocks powered higher on Wednesday as the Federal Reserve said it saw signs of a more stable economy. The DJIA gained 120.16 pts, or 1.30% to close at 9,361.61, the S&P 500 rose 11.46 pts, or 1.15%, to close at 1,005.81, leading NAS tallied up + 28.99 pts, or 1.47%, to close at 1,998.72, and the Russell 2000 closed up 10.05 pts, or 1.8%, to end the session at 572.17. Shares of luxury home builder Toll Brothers TOL.N soared 14.4% to US$23.42 after it said its net signed contracts rose in Q-3, the first increase in about four years. Shares of Macy's Inc M.N rose 6% to US$16.40 after the department store operator posted better-thanexpected earnings and raising its outlook going forward. Volume was low on the NYSE, with 1.2B/shrs changing hands, below last year's estimated daily average of 1.49 billion, and on the NAS about 631.1M/shrs traded, well below last year's daily average of 2.28B/shrs. Advances outnumbered decliners on the NYSE by a ratio of 3 to 1, and on the NAS equally 3 to 1.
Stocks to Watch Today Cell Therapeutics Inc (CTIC), Toll Brothers Inc (TOL), Wuxi PharmaTech Inc (WX), and Wynn Resorts Ltd (WYNN).
Cell Therapeutics, Inc. (CTIC) Update (2)
August 13, 2009 Paul A. Ebeling, Jr. Analyst Today, letâ€™s look at Cell Therapeutics, Inc. (CTIC), the toxic avenger biotech company, from a Technical POV. The overall analysis after Wednesdayâ€™s (August 12, 2009) market action is Bullish: in the near term Bullish, mid-term Bullish and long term Bullish. The recent Candle Stick analysis is: Bullish
**Chart by: http://www.stockta.com
Latest News: Star Analysts look at CTIC
Wednesdayâ€™s Market Action Close 1.61
There is an Inverted Hammer on Aug 10, and four Gaps open up in the month of May, 2009 at .01/1.26, the near term resistance is 1.87, support at 1.57, and the 50 day (EMA) exponential moving average is 1.42. This is Cell Therapeutics, Inc. (CTIC): Cell Therapeutics, Inc., is a biopharmaceutical company that develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkinâ€™s lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P. The company was founded in 1991 and is headquartered in Seattle, Washington. Competitive Landscape Demand for biotechnology products and services are driven primarily by the willingness of insurers to pay for new medical treatments. The profitability of individual companies depends on the discovery and effective marketing of new products. Because the market for potential products is so large, small biotechnology companies can co-exist successfully with large ones if they have expertise in a particular line of research. Biotechnology Sector Industry Forecast The output of US scientific research and development, an indicator of biotechnology activity, is forecast to grow at an annual compounded rate of 9 % between 2008 and 2013. Data Sourced: December 2008 Cell Therapeutics, Inc. (HQ) James A. Bianco, M.D., Principal Founder, Chief Exec. Officer & Exec. Director 501 Elliott Avenue West Suite 400 Seattle, WA 98119 United States Phone: 206-282-7100 Fax: 206-284-6206 http://www.cticseattle.com
Toll Brothers Inc. (TOL) Up-date 1
August 13, 2009 Paul A. Ebeling, Jr. Analyst Today let’s look at Toll Brothers Inc. (TOL), a top USA builder of luxury homes, from a Technical POV. The overall indications, after Wednesday’s (August 12, 2009) market action, are Neutral: in the near term Neutral, mid-term Bullish, and long term Neutral. The recent Candle Stick analysis is: Neutral
**Chart by: http://www.stockta.com
Latest News: Toll Says Home Buyers Tiptoe Back
http://online.wsj.com/article/SB125007314213725605.html?ru=yahoo#mod=yahoo_hs Wednesday Market Action
There is a Bearish Engulfing pattern August 6 and Gap open up Jul 15/Aug 12 2009 16.12/16.33 & 20.87/22.15, there is no near term resistance, support starts at 22.15, and the 50 day (EMA) exponential moving average is 18.71. This is Toll Brothers Inc. (TOL): This Company is a top US builder of luxury homes, builds for move-up, empty-nester, active-adult, and second-home buyer markets in more than 300 suburban communities in some two dozen states. Its single-family detached homes and apartments range from US$229,000 to about $2.16 million. Toll Brothers develops active-adult communities (some with golf courses) and operates country club communities. Through subsidiaries, it offers insurance, landscaping, and title and mortgage services. Toll delivered nearly 8,600 homes in 2006 but that figure dropped precipitously to about 6,700 in 2007 and just over 4,800 in 2008. Competitive Landscape Demand for new housing depends on population growth and is linked to low interest rates. Large builders have some advantages in purchasing and marketing, but building methods are essentially the same for large or small builders. While larger builders have efficiencies because they can repeatedly build the same home models, they generally develop projects on large pieces of land. Small builders, therefore, build most homes in dense urban markets where little land is available. Residential Real Estate Construction Industry Forecast The value of US new residential home construction and renovations is forecast to grow at an annual compounded rate of 7% between 2008 and 2013. Data Sourced: December 2008
Toll Brothers Inc. (HQ) Robert I. Toll Co-Founder, Chairman and Chief Exec. Officer 250 Gibraltar Road Horsham, PA 19044 United States Phone: 215-938-8000 Fax: 215-938-8010
WuXi PharmaTech (WX) Up-date 1 August 13, 2009 Paul A. Ebeling, Jr. Analyst Today letâ€™s look at WuXi PharmaTech (WX), provides laboratory and manufacturing services for customers in the pharmaceutical, biotechnology, and medical equipment industries, from a Technical POV. The overall indications, after Wednesdayâ€™s (August 12, 2009) market action, are Very Bullish: in the near term Bullish, mid-term Very Bullish, and long term Very Bullish. The recent Candle Stick analysis is: Very Bullish
**Chart by: http://www.stockta.com
Latest News: WuXi 2Q profit rises on Margins, Lower Costs http://biz.yahoo.com/ap/090812/us_earns_wuxi_pharmatech.html?.v=1 Wednesday â€˜s Market Action
Close 12.50 + 2.00
There is a Bullish Harami on August 11 and two Gaps open up on between May 15, and Aug 12, 2009 at 5.75/11.00, the near term resistance is NIL, support at 11.37, and the 50 day (EMA) exponential moving average is 9.09. This is WuXi PharmaTech (WX): The Company provides laboratory and manufacturing services for customers in the pharmaceutical, biotechnology, and medical equipment industries. Its core lab services business offers contract research, discovery chemistry, service biology, device testing, and pharmaceutical development services. WuXi's ancillary manufacturing operations mainly produce advanced intermediate drugs, biologics-based drugs, and active drug ingredients. Top customers include leading global drug makers Pfizer and Merck. Competitive Landscape Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. The profitability of individual companies depends on the discovery and effective marketing of new products. Because the market for potential products is so large, small biotechnology companies can co-exist successfully with large ones if they have expertise in a particular line of research. Biotechnology Sector Industry Forecast
The output of US scientific research and development, an indicator of biotechnology activity, is forecast to grow at an annual compounded rate of 9% between 2008 and 2013. Data Sourced: December 2008 WuXi PharmaTech (Cayman) Inc. (HQ) Ge Li Ph.D., Co-Founder, Chairman, Chief Exec. Officer 288 FuTe ZhongLu Waigaoqiao Free Trade Zone Shanghai, 200131 Phone: 86 21 5046 1111 Fax: 86 21 5046 1000
Wynn Resorts Ltd. (WYNN) Up-date 3 August 13, 2009, 2009 Paul A. Ebeling, Jr. Analyst Today letâ€™s look at Wynn Resorts Ltd. (WYNN), the brainchild of gaming wizard Steven Wynn, from a Technical POV. The overall indications, after Wednesday (August 12, 2009, 2009) market action, are Neutral: in the near term Bullish, mid-term Bullish, and long term Neutral. The recent Candle Stick analysis is: Neutral
**Chart by: http://www.stockta.com
Latest News: Wynn Resorts has the best balance sheet of the casino stocks
http://www.thestreet.com/_yahoo/story/10572740/1/cramers-stop-trading-get-smartphone.html? cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA Wednesdayâ€™s Market Action Close 59.52
There are five Gaps open up between Apr 2, and Aug 3, 2009 at 21.64/52.23, the near term resistance is 62.21, support at 57.32, and the 50 day (EMA) exponential moving average is 43.71 This is Wynn Resorts Ltd. (WYNN): Wynn Resorts is the brainchild of gaming mogul and former Mirage Resorts chairman Steve Wynn. The US$2.4B resort and casino, built on the site of the former Desert Inn on the Las Vegas Strip, boasts more than 2,700 rooms, a casino with nearly 2,000 slots and about 140 table games, some 20 restaurants, a golf course, an art gallery (featuring Wynn's personal collection), two wedding chapels, and a Ferrari and Maserati dealership. Wynn Resorts also includes Encore at Wynn Las Vegas, a hotel and casino adjacent to its Wynn Las Vegas property, and the Wynn Macau, a hotel and casino in China. Steve Wynn owns about 21% of the company. Competitive Landscape Growth in consumer income and state spending has driven expansion of the US gambling industry. The profitability of individual companies depends on efficient operations and effective marketing. Large operators have the financial resources to make large investments in facilities and efficient computer operations, and have cross-marketing opportunities. Small gambling facilities can thrive by catering to a local clientĂ¨le. The industry is fairly labor-intensive: annual revenue per employee is US$90,000. Gambling Operations Industry Forecast
US personal consumption expenditures for participant amusements and pari-mutuel net receipts, which include gambling operations, are forecast to grow at an annual compounded rate of 4 % between 2008 and 2013. Data Sourced: December 2008 Wynn Resorts Ltd. (HQ) Chairman and Chief Executive Officer: Stephen A. Wynn 3131 Las Vegas Boulevard South Las Vegas, NV 89109 United States Phone: 702-770-7555 Fax: 702-770-1571 http://www.wynnresorts.com
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them. Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research. Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing. This website is a service of BlueWave Advisors, LLC, a financial public relations firm that has been compensated by the companies profiled. All direct and third party compensation received has been disclosed within each individual profile in accordance with section 17(b) of the Securities Act of 1933. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. BlueWave Advisors, LLC, and/or its affiliated will hold, buy, and sell securities in the companies profiled. When compensated in shares, all readers should be aware that is our policy to liquidate all shares immediately. We reserve the right to buy or sell the shares of any the companies mentioned in any materials we produce at any time. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies. Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no firsthand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).
We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.